Research into the Monoclonal Antibody GC33 for HCC

Video

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).

Clinical Pearls

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).

  • GC33 is a humanized monoclonal antibody against GPC3 that is frequently expressed in HCC.
  • In aphase Ib dose escalation study, GC33 was looked at in combination with sorafenib. Though GC33 showed questionable tolerability, the agent will be looked at with a biomarker component in a future trial.
  • Aphase II triallooking at GC33 in previously treated patients with HCC was also negative.
Recent Videos
Related Content
Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Jordyn Sava
April 1st 2025
Article

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Read More

Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Teclistamab, Daratumumab, Pomalidomide Is Feasible in Multiple Myeloma

Jordyn Sava
March 22nd 2025
Article

Anita D'Souza, MD, discussed the results from the MajesTEC-2 and TRIMM-2 trials in patients with multiple myeloma.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Dr Long Highlights Long-Term Benefit of Dabrafenib/Trametinib in Melanoma

Jordyn Sava
March 19th 2025
Article

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib in stage III BRAF-mutated melanoma.

Read More